Search
Ivacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIvacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. … [L6841] Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.
Maribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalMaribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients. … [L39322] Most standard CMV therapies, such as [ganciclovir] or [foscarnet], target CMV DNA polymerase - while generally effective, these medications tend to promote the development of CMV resistance to
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseBrilliant blue G
go.drugbank.com/drugs/DB15594ApprovedIt was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.
Categories: Compounds used in a research, industrial, or household settingAvacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV. … [L38919] On January 19, 2022, the European Commission approved avacopan for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) - the
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalIt is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb.
Oxybenzone
go.drugbank.com/drugs/DB01428ApprovedOxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents. It is used as an ingredient in sunscreen and other cosmetics because...
Mixtures: SPF 8 Sun Protection for All Seasons, SPF 30 Sun Protection for All SeasonsCategories: Compounds used in a research, industrial, or household settingCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [A243351, A243361, L39411] Cilgavimab is not approved for any indication by the FDA.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [A243351, A243361, L39411] Tixagevimab is not approved for any indication by the FDA.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseLomitapide
go.drugbank.com/drugs/DB08827Approved[A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: JUXTAPID® CÁPSULAS POR 20 MG, JUXTAPID® CÁPSULAS POR 5 MGAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalKRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.